COCH Envoy Medical, Inc. Insider Trading

Director Patel Mona Chetan bought 312.5K shares of COCH at $0.40 (Feb 2026); part of 5-insider cluster buy amid -28.8% annual revenue decline and negative net income.

Director Patel Mona Chetan purchased 312,500 shares at $0.40 per share on 2026-02-12, increasing her holdings from 20,000 to 332,500 shares—a 1562.5% increase in position size. This transaction is part of a cluster in which 5 other insiders also bought within the past 14 days, suggesting coordinated board-level activity. However, the company's fundamentals present significant headwinds: revenue declined 28.8% year-over-year to $42,000 in the latest quarter, the company generated negative net income of $-6,482,000 over its most recent full fiscal year, and market cap stands at only $19,862,692.59. The insider's same-ticker history at COCH shows 5 prior buys with a 0% win rate at the 90-day mark (all five resulted in losses within 90 days), establishing a pattern of poorly-timed accumulation at this ticker. Current price of $0.69 represents a 59.9% decline from the 52-week high of $1.72, yet the stock remains above the $0.39 52-week low—leaving material downside risk in a cash-constrained, revenue-declining business.

10% owner Taylor Glen A purchased 18,750,000 shares at $0.40 for $7,500,000 on 2026-02-12; post-transaction holdings 21,703,607 shares (+634.8%)

A 10% owner acquired 18,750,000 shares for $7,500,000 on 2026-02-12, increasing holdings from 2,953,607 to 21,703,607 shares—a 634.8% increase. This substantial capital commitment by a major shareholder occurs amid a cluster of 5 other insider purchases within the past 14 days, suggesting coordinated confidence at the current price point. The company faces significant headwinds: quarterly revenue of $42,000, a net loss of $6,482,000, annual revenue decline of -28.8%, and a market cap of $19,862,692.59. The current stock price of $0.69 has declined 59.9% from its 52-week high of $1.72, creating a valuation context for the transaction at $0.40. The concurrent cluster buying pattern and the magnitude of this insider's capital deployment warrant investor scrutiny of the underlying business fundamentals and the insiders' investment thesis in a distressed financial scenario.

Director Kantor buys 96,150 shares of Envoy Medical at $0.40; 5 other insiders also bought within 14 days as stock trades at $0.69, down 59.9% from 52-week high.

Susan Kantor, a director, purchased 96,150 shares at $0.40, increasing her holdings by 123.4% to 174,037 shares. The transaction occurred within a 14-day window in which 5 other insiders also initiated buys, forming a notable cluster purchase pattern. This coordinated accumulation by multiple insiders is noteworthy given the company's operational stress: Envoy Medical reported only $42,000.00 in revenue in its latest quarter, posted a negative net income of $-6,482,000.00, and experienced -28.8% annual revenue decline while remaining unprofitable. The current stock price of $0.69 remains 59.9% below the 52-week high of $1.72, and the director's purchase price of $0.40 sits near the 52-week low of $0.39, suggesting accumulation at severely depressed levels. Without scheduled trading plan disclosures or alternative context, the coordinated insider buying pattern warrants scrutiny as to whether these transactions reflect private information about a recovery path or other material developments not yet public.

Director Bryn Elsen bought 1,000,000 shares of COCH at $0.40; stock now $0.69 but holder of 2,000.0% prior-holding increase amid cluster activity

Charles Bryn Elsen (Director) purchased 1,000,000 shares at $0.40 on 2026-02-12, raising his holdings from 50,000 to 1,050,000 shares. The buy occurred at $0.39–$1.72 52-week range lows and represents a 2000.0% increase relative to his pre-transaction holdings. However, his cross-ticker track record shows 3 prior buys with an average 90-day return of -28.3% and a 0.00% win rate, while his same-ticker history at COCH shows three consecutive buys (2025-05-22, 2025-05-23, 2025-05-27), each generating negative 90-day returns (-24.6%, -28.2%, -32.0% respectively). Envoy Medical reported revenue of $42,000.00 in the latest quarter, net income of $-6,482,000.00, annual revenue decline of -28.8%, and a market cap of $19,862,692.59 while unprofitable. The transaction occurred alongside 5 other insider buys within 14 days, forming a cluster pattern, though the fundamental weakness and insider timing history suggest caution.

CEO Lucas Brent T. bought 62,500 shares of COCH at $0.40 amid cluster buy pattern; stock -59.9% from 52-week high on -28.8% revenue decline.

CEO Lucas Brent T. purchased 62,500 shares (62.5K shares) at $0.40, raising his holdings by 26.6% from 234,590 shares to 297,090 shares. This transaction occurs within a cluster pattern where 5 other insiders also bought within the past 14 days, suggesting coordinated conviction at these price levels. However, the company's fundamentals present a challenge to interpret this positively: revenue contracted -28.8% year-over-year, the company posted net income of $-6,482,000.00 ($-6.5M) in its most recent full fiscal year, and the stock currently trades at $0.69, down 59.9% from its 52-week high of $1.72. While the CEO's prior trades at COCH showed strong post-purchase returns (+129.6% and +144.6% over 30 days), current valuation context and deteriorating financials create material downside risks that offset historical timing success.

Interim CFO Potashnick buys 212.5K shares at $0.40; cluster of 5 other insider buys in 14 days as stock trades -59.9% from 52-week high.

Interim CFO Robert Potashnick purchased 212,500 shares at $0.40 on 2026-02-12, representing a new position at a price 42.0% below the current price of $0.69 and 76.7% below the 52-week high of $1.72. The transaction occurs within a 14-day cluster in which 5 other insiders also executed purchases, suggesting coordinated or coincident confidence among multiple executives. Envoy Medical faces material headwinds: the company posted $-6,482,000.00 net income in its most recent fiscal year, reported only $42,000.00 in latest-quarter revenue, and experienced -28.8% annual revenue decline year-over-year, with a $19,862,692.59 market cap. The concurrent buying by Potashnick and peers against a backdrop of significant operating losses and revenue contraction warrants investor scrutiny of whether purchases reflect conviction in turnaround momentum or whether planned operational initiatives support renewed execution.

Director Patel Mona Chetan bought 2,500 shares at $1.47 on 2025-06-11; stock now down -19.4% in 30d, -63.2% from 52w high, within weak track record pattern.

Director Patel Mona Chetan purchased 2,500 shares at $1.47 on 2025-06-11, increasing holdings from 17,500 shares to 20,000 shares. This marks the insider's fifth buy at Envoy Medical within nine months, following purchases on 2025-06-06, 2024-11-20, 2024-09-11, and 2024-09-09. Across his prior four buys at this ticker, none resulted in positive 90-day returns—outcomes ranged from -10.9% to -36.8%—revealing a consistent pattern of poorly-timed entry points. The stock is currently trading at $1.37, down 19.4% over 30 days and down 63.2% from its 52-week high of $3.72, and the company reported a net loss of $5.0M against quarterly revenue of $46.0K with annual revenue growth declining 28.8%, indicating fundamental deterioration. The recurrence of buy activity despite this unfavorable combination of technical weakness, fundamental losses, and the insider's own poor historical timing at this ticker warrants attention to whether capital constraints or other pressures are driving these purchases rather than conviction in recovery.

Director Patel purchases 10,000 COCH shares at $1.46; stock -60.2% from 52-week high, company unprofitable with -28.8% revenue decline

Mona Chetan Patel, a Director, purchased 10,000 shares at $1.46 on 2025-06-06, increasing her holdings by 133.3% to 17,500 shares. The timing warrants caution: at $1.48 current price, the stock is -60.2% from its 52-week high of $3.72, yet her prior three purchases at COCH have all resulted in negative 90-day returns (-27.6%, -36.8%, -19.8%, -35.7%, and -10.9%, -31.2%), with a 0% win rate at this ticker. Fundamentally, Envoy Medical reported a net loss of $-5.0M against quarterly revenue of $46.0K, with annual revenue declining 28.8% year-over-year and a market cap of only $31.6M. The director's accumulation pattern at a distressed valuation does not offset the company's deepening profitability and growth challenges.

Director Charles Brynelsen purchased 50,000 shares for $82,402.70 across 3 transactions at Envoy Medical (COCH), blended avg $1.65.

Charles Brynelsen, a director at Envoy Medical, acquired a 50,000 share position through 3 separate purchases between May 22–27, 2025, at prices ranging from $1.64 to $1.68 per share. This represents a new position (0 shares pre-transaction). The company faces significant headwinds: annual revenue declined 28.8% year-over-year, the latest quarterly revenue was $46,000.00, net income is negative at $-5.0M, and market cap is $33.3M. The stock is currently trading at $1.56, down 58.1% from its 52-week high of $3.72, although it has risen 5.4% over the past 30 days and 13.9% over 90 days. The director's entry at $1.65 occurred in the context of steep valuation declines and operational deterioration, adding to the observed recent price rebound but without evidence of a fundamental inflection.

Director Patel buys 2,500 shares of COCH at $2.28, holding now 7,500 shares; stock down -78.1% from 52-week high amid unprofitability.

Director Mona Chetan Patel purchased 2,500 shares at $2.28 on 2024-11-20, increasing her holdings by 50.0% from 5,000 to 7,500 shares. The transaction occurs while the stock trades at $2.18, down -78.1% from its 52-week high of $9.95 and has declined -15.2% over 30 days. At the same ticker, Patel's prior two purchases (2024-09-11 and 2024-09-09) recorded negative 30-day returns of -19.8% and -10.9% respectively. The company is unprofitable with net income of $-6.0M despite quarterly revenue of $56.0K and positive annual growth of +33.3%, creating a high-risk profile. The buy pattern—accumulating shares into a depressed stock with a weak near-term trend and unfavorable prior-trade outcomes at this ticker—reflects continued exposure to a speculative position without evidence of improved fundamentals or price stabilization.